<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:406922173;
mso-list-template-ids:-1519601960;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:799760586;
mso-list-template-ids:34009646;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:843204949;
mso-list-template-ids:-297599098;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:2094203713;
mso-list-template-ids:-197467592;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-235.html" target="_blank">NIMHD Exploratory/Developmental Research Grant Program (R21 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual
stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary
work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3.
</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-180.html">Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 – Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a
wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services
for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability,
and utility of these approaches, in addition to usual trial preparation activities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-021.html">Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic,
and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities,
obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide
information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative
agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 1, 2021; October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; and February 20, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for July 1, 2021 due date: June 21.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-020.html" target="_blank">NINDS Research Program Award (R35, Outstanding Investigator Award, Clinical Trial Optional)<span style="font-family:"Calibri",sans-serif"></span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs),
to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research
goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates , which support and align with the
<a href="https://www.ninds.nih.gov/about-ninds/who-we-are/mission">mission of NINDS</a>. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI’s recent NINDS support (Part 2, Section
II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 13, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 29 (due to July 4 holiday).</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=92850">Family-Centered Approaches to Improving Type 2 Diabetes Control and Prevention</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Office of the Assistant Secretary for Health / Office of Minority Health solicits applications to fund projects that test interventions to identify family-centered factors that promote
self-management and prevention of Type 2 diabetes among racial and ethnic minority and disadvantaged families who have a member(s) aged 12 and older with Type 2 diabetes. Through the testing of family-centered interventions, OMH expects the Family-Centered
Approaches to Improving Type 2 Diabetes Control and Prevention initiative to identify specific family-centered factors (e.g., structural, instrumental, functional, cultural and social needs) that affect patient self-management of diabetes (e.g., physical activity,
healthy nutrition) and family members’ health outcomes. The target population for the intervention is racial/ethnic minority and disadvantaged families with a family member(s) aged 12 and older with Type 2 diabetes. For the purposes of this notice, “family”
also includes persons who may live in the same household as the individual with Type 2 diabetes. 2-year projects; $500,000 per year.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 13, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 29 (due to July 4 holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-031.html">Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors
Consortium (U01 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) seeks to support exercise and/or medical nutrition intervention research designed to improve cancer
treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors. Projects may include either pediatric or adult cancer patient populations and must identify a treatment-related outcome as a primary endpoint and
specify a relevant patient-reported secondary outcome(s). Priority will be given to studies with direct clinical relevance and translational potential. Responsive applications will fill a research gap concerning the efficacy of specific exercise and dietary
approaches to improve cancer treatment-related outcomes. Information gained should improve behavioral intervention protocols for cancer survivors undergoing cancer treatment and may also generate feasibility information concerning translation into clinical
care. Awardees will participate in an Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 30 (due to July 4 holiday).</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/mrp" target="_blank">Melanoma Research Program</a><br>
<b>Idea Award</b><br>
Pre-application (pre-proposal): June 29. Invited full application: September 28.<br>
<b>Melanoma Academy Scholar Award<br>
</b>Pre-application (pre-proposal): June 29. Invited full application: September 28.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-proposal: June 19.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Melanoma Academy Leadership Award</b><br>
Pre-application (required letter of intent): August 4. Full application: August 26.<br>
<b>Mid-Career Accelerator Award</b><br>
Pre-application (required letter of intent): August 4. Full application: August 26.<br>
<b>Team Science Award</b><br>
Pre-application (required letter of intent): August 4. Full application: August 26.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: August 16.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/msrp" target="_blank">Multiple Sclerosis Research Program</a><br>
<b>Clinical Trial Award</b><br>
Pre-application (pre-proposal): June 30 Invited full application: October 1.<br>
<b>Exploration – Hypothesis Development Award</b><br>
Pre-application (pre-proposal): June 30 Invited full application: October 1.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (pre-proposal): June 30 Invited full application: October 1.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-proposal: June 17.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Early Investigator Research Award<br>
</span></b><span style="font-size:12.0pt;font-family:Palatino">Pre-application (required letter of intent): September 7. Full application: October 1. Confidential letters of recommendation: July 7.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: September 20.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<a href="https://cdmrp.army.mil/funding/nfrp" target="_blank">Neurofibromatosis Research Program</a><br>
<b>Clinical Trial Award</b><br>
Pre-application (required letter of intent): July 8. Full application: July 22. <br>
<b>Early Investigator Research Award<br>
</b>Pre-application (required letter of intent): Pre-application (required letter of intent): July 8. Full application: July 22. Confidential letters of recommendation: July 27.<br>
<b>Exploration – Hypothesis Development Award</b><br>
Pre-application (required letter of intent): July 8. Full application: July 22. <br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (required letter of intent): July 8. Full application: July 22. <br>
<b>New Investigator Award<br>
</b>Pre-application (required letter of intent): July 8. Full application: July 22.
<b><br>
Synergistic Idea Award<br>
</b>Pre-application (required letter of intent): July 8. Full application: July 22.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: July 12.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-205.html">Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for
People Who Use Drugs (R34 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions for people who use drugs. Primary outcomes of interest
include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. “Intervention” here may include behavioral, social, or structural approaches, as well as combination
biomedical and behavioral approaches that prevent the acquisition or transmission of HIV infection, or improve clinical outcomes for persons living with HIV.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard AIDS dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for September 7 standard AIDS date: August 24 (due to Labor Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505730&WT.mc_id=USNSF_39&WT.mc_ev=click">NSF: Science of Science: Discovery, Communication, and Impact (SoS:DCI)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Science of Science: Discovery, Communication, and Impact (SoS:DCI) program is designed to increase the public value of scientific activity. The program pursues this goal by supporting
basic research in three fundamental areas: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">How to increase the rate of socially beneficial discovery;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">How to improve science communication outcomes; and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">How to expand the societal benefits of scientific activity. <o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The SoS:DCI program, which builds upon the former Science of Science & Innovation Policy (SciSIP) program, funds research that builds theoretical and empirical understandings of these
three areas. With this goal in mind, proposals should: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Develop data, models, indicators, and associated analytical tools that constitute and enable transformative advances rather than incremental change. <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Identify ethical challenges and mitigate potential risks to people and institutions. <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Provide credible metrics and rigorous assessments of their proposed project’s impact.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Include robust data management plans with the goal to increase the usability, validity, and reliability of scientific materials.
<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Of particular interest are proposals that have the highest potential to strengthen America’s global leadership in science and increase national competitiveness across a broad range of
domains. These include proposals that analyze strategies for strengthening and diversifying the scientific workforce, as well as ways to more effectively cultivate high-impact discovery across sectors. The program strongly encourages convergent research and
collaboration.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 9, 2021; February 11, 2022; and September 9, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for September 9, 2021 due date: August 26 (due to Labor Day holiday).<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-001.html">T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed; Predoctoral or
Postdoctoral options)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from diverse backgrounds, including those from groups that are nationally underrepresented
in cardiovascular, pulmonary, hematologic and sleep disorders research across the career development continuum by providing support to institutions that promote diversity. The NHLBI’s T32 Training Program for Institutions That Promote Diversity is a Ruth L.
Kirschstein National Research Service Award Program intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations
not well represented in scientific research, or institutions that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary,
and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to engage minority and other health disparity populations in research, translation, and implementation of research advances that impact health outcomes, as well as provide
health care for these populations. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 13, 2021; February 28, 2022; September 13, 2022; February 28, 2023; September 13, 2023; and February 28, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for September 13, 2021 due date: August 30 (due to Labor Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-223.html" target="_blank">NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for
and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (<a href="http://www.ninds.nih.gov/funding/areas/index.htm">www.ninds.nih.gov/funding/areas/index.htm</a>).
Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with
the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site
implementation of the clinical protocol.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Applicants do not need to be part of the existing NeuroNEXT infrastructure.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires March 6, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5 standard date: September 22.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-236.html">NINDS Exploratory Clinical Trials (U01 – Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological
Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission
and research interests of the NINDS can be found at the NINDS website.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 5, 2021 and February 5, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 due date: September 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-020.html">Human Milk as a Biological System (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in our understanding of human milk as a biological system and that expand our understanding
of the myriad factors influencing the composition and function of human milk using a systems biology approach. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 29, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html">Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects
including structural birth defects (SBDs), intellectual developmental disabilities (IDDs), and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through
several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening,
functional validation, and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models,
<i>in vitro</i> systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 5, 2022; June 5, 2022; February 5, 2023; June 5, 2023; February 5, 2024; June 5, 2024; and February 5, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for February 5, 2022 due date: January 25.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-168.html" target="_blank">Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Research Education Program (R25) supports research educational activities that complement other formal training programs in the mission areas of the NIH Institutes and Centers.
The over-arching goals of the NIH R25 program are to: (1) complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs; (2) encourage individuals from diverse backgrounds, including those from
groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research; (3) help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical
sciences; and (4) foster a better understanding of biomedical, behavioral and clinical research and its implications.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Research Experiences:
</span></b><span style="font-size:12.0pt;font-family:Palatino">For high school students, undergraduate students, and/or science teachers during the summer academic break. Proposed programs should provide authentic “open-ended”, hands-on exposure to research
in a laboratory or a field setting as part of a comprehensive program based in sound educational practices designed to stimulate the interest and advance the knowledge base of participants. In addition to hands-on research experiences, programs are expected
to include complementary activities that support the participants’ scientific development, such as scientific writing and presentation skills and training in rigor and reproducibility. Programs should consider the needs of the intended participants and the
likelihood of improving their knowledge and/or skills when designing the research program. Programs should have clear goals and objectives appropriate for the educational level of the audience to be reached (high school and/or undergraduate students or science
teachers), including the content to be conveyed, and the intended outcome(s). Outcomes for high school and college students may include: to reinforce their intent to graduate with a science degree, prepare them for graduate or medical school admissions, and/or
prepare them for careers in research. Support for science teachers will be limited to those programs with a clear plan for how teachers will utilize their summer experience in their teaching during the school year, such as enhancing the STEM curriculum or
increasing number of STEM courses taught.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">R25 programs that propose at least 8 weeks, but fewer than 15 weeks, of full-time research experiences during the summer may request continued part-time support for the participants to
work on their research projects during the school year, up to the equivalent of a total of 15 weeks of full-time participation, as long as the entire research experience is completed within a 12-month period. Applications that demonstrate the potential to
impact students and teachers from diverse backgrounds are particularly encouraged. All programs are expected to promote inclusive research environments (i.e., institutional and departmental environments in which trainees from all backgrounds feel integrated
into and supported by the biomedical community.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The proposed program needs to align with the mission of the IC to which the application is submitted and not have a general STEM focus. ICs will not support projects, regardless of the
results of merit review, if they do not fulfill current programmatic priorities. Therefore, it is strongly recommended that potential applicants consult scientific/research staff at the intended IC listed in Section VII before preparing an application. For
the specific ICs, the following represents mission focus areas (more information can be found in the Table of IC-Specific Information and Contacts page):<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo4"><b><span style="font-size:12.0pt;font-family:Palatino">NIAAA</span></b><span style="font-size:12.0pt;font-family:Palatino"> broadly encourages research that focuses on the following 5 goals: (1) identifying
the mechanism of; (2) improve diagnosis and tracking of; (3) develop and improve strategies to prevent; and (4) develop and improve treatments for alcohol misuse, alcohol use disorder and alcohol-related consequences; and (5) enhance the public health impact
of NIAAA-supported research.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo4"><b><span style="font-size:12.0pt;font-family:Palatino">NIBIB</span></b><span style="font-size:12.0pt;font-family:Palatino"> will support applications focusing on summer research experiences broadly in the
areas of biomedical imaging, bioengineering, or health informatics. NIBIB will only support programs for high school science teachers and community college faculty from STEM-related departments, and not for students.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo4"><b><span style="font-size:12.0pt;font-family:Palatino">NIDA</span></b><span style="font-size:12.0pt;font-family:Palatino"> will support applications focusing on identifying the biological environmental,
behavioral, and social causes and consequences of drug use and addiction across the lifespan, including research in basic science. Applications should seek to develop new and improved strategies to prevent drug use and its consequences; new and improved treatments
to help people with substance use disorders achieve and maintain a meaningful and sustained recovery, as well as increase the public health impact of NIDA research and programs.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo4"><b><span style="font-size:12.0pt;font-family:Palatino">NIEHS</span></b><span style="font-size:12.0pt;font-family:Palatino"> will support applications focusing on summer research experiences in the environmental
health sciences. Applications to NIEHS should provide research experiences that address or seek to understand how exposures to toxic environmental insults impact health, alter biologic processes, are linked to disease initiation, progression or morbidity,
or activities that lead to the development of prevention and intervention strategies to reduce environmentally induced diseases.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo4"><b><span style="font-size:12.0pt;font-family:Palatino">NINDS</span></b><span style="font-size:12.0pt;font-family:Palatino"> will support applications focusing on summer research experiences that address
or seek fundamental knowledge about the brain and nervous system by supporting and conducting research on the healthy and diseased brain, spinal cord, and peripheral nerves and to use that knowledge to reduce the burden of neurological disease. NINDS also
encourages activities focused on understanding and addressing disparities in neurologic health, healthcare, and health outcomes in disparate populations, including racial and ethnic minorities, the geographically disadvantaged, sex and gender minorities, and
others who have been historically underserved, marginalized, and adversely affected by persistent inequality and socioeconomic disadvantage. NINDS supports basic, translational, and clinical research:
<a href="https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS">https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS</a><o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 17, 2022; March 17, 2023; and March 19, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for March 17, 2022 due date: March 9<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b><o:p></o:p></span></p>
</div>
</body>
</html>